Transcend Medical, a Menlo Park, Calif.-based device company focused on minimally invasive treatments for glaucoma patients, has joined the randomized, multicenter, prospective, controlled COMPASS trial that is studying the CyPass Micro-Stent.
The CyPass Micro-Stent, designed as a minimally invasive device to decrease intraocular pressure in glaucoma patients, is being tested in over 20 locations in the US and has been utilized in over 500 glaucoma patients receiving cataract surgery.
Transcend Medical has completed enrollment for the COMPASS study. Transcend Medical and the participants of COMPASS hope to soon bring the CyPass Micro-Stent to the FDA for approval.
More Articles on Ophthalmology:
Ocular Therapeutix Seeking FDA Approval for ReSure Sealant
TearScience Receives $70M in Funding
6 New Ophthalmology-Driven Facilities
The CyPass Micro-Stent, designed as a minimally invasive device to decrease intraocular pressure in glaucoma patients, is being tested in over 20 locations in the US and has been utilized in over 500 glaucoma patients receiving cataract surgery.
Transcend Medical has completed enrollment for the COMPASS study. Transcend Medical and the participants of COMPASS hope to soon bring the CyPass Micro-Stent to the FDA for approval.
More Articles on Ophthalmology:
Ocular Therapeutix Seeking FDA Approval for ReSure Sealant
TearScience Receives $70M in Funding
6 New Ophthalmology-Driven Facilities